Storage bag for containing therapeutic compounds

US11278471B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11278471-B2
Application numberUS-201916690274-A
CountryUS
Kind codeB2
Filing dateNov 21, 2019
Priority dateJul 31, 2014
Publication dateMar 22, 2022
Grant dateMar 22, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A storage bag configured to contain or that contains at least one therapeutic compound such as a viral vector and non-viral vector is provided. In one embodiment, the storage bag contains a viral vector and/or a non-viral vector containing genetic material. The storage bag has two edges and two ends including a first face and a second face integrally joined at the two edges of the bag and defining an inner surface and an outer surface forming the bag; the inner surface including a higher melting polymer, and the outer surface including a lower melting polymer; a joint at one of the ends; a discrete composite sheet having a first side including a higher melting polymer and a second side including a lower melting polymer folded over the joint with the first side including a lower melting polymer engaging the joint to form a lap seam over the joint.

First claim

Opening claim text (preview).

What is claimed is: 1. A storage bag comprising: a composite tube extending from a first end to a second end of the bag, the composite tube having an inner surface and an outer surface, the inner surface including a higher melting polymer and the outer surface including a lower melting polymer, wherein a portion of the inner surface overlaps a portion of the outer surface to form a first lap seam extending from the first end to the second end; a first joint at the first end; a second joint at the second end; and a first composite sheet having a first side including the higher melting polymer and a second side including the lower melting polymer, wherein the first composite sheet is folded over the first joint such that the second side is engaged with the first joint to form a second lap seam over the first joint, wherein the storage bag has an internal reservoir, and wherein the internal reservoir contains therein at least one therapeutic compound. 2. The storage bag of claim 1 , wherein the therapeutic compound comprises viral vectors, non-viral vectors, and combinations thereof. 3. The storage bag of claim 2 , wherein the viral vectors include lentiviruses, adeno associated viruses (AAV), adenoviruses, alphaviruses, herpes simplex, measles virus, newcastle disease virus (NDV), picornaviruses, poxviruses, retroviruses, rhabdoviruses and combinations thereof. 4. The storage bag of claim 2 , wherein the viral vectors include lentiviruses and adeno associated viruses. 5. The storage bag of claim 4 , wherein the adeno associated viruses comprise AAV-MeCP2, AAV1, AAV5; Dual AAV9, AAV8, AAV9, AAVrh10, AAVhu37, AAV-FVIII/FIX and mutations and combinations thereof. 6. The storage bag of claim 4 , wherein the lentiviruses comprise HIV-1, HIV-2, Lenti-FVIII, Lenti-FIX, and mutations and combinations thereof. 7. The storage bag of claim 1 , wherein the therapeutic compound comprises bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides, signal transduction molecules, vaccines, and mutations and combinations thereof. 8. The storage bag of claim 1 , wherein the therapeutic compound comprises at least one bioactive selected from antibodies, antisense, RNA interference, target receptors, and mutations and combinations thereof. 9. The storage bag of claim 1 , wherein the therapeutic compound comprises at least one bioactive selected from protein kinases, esterases, phosphatases, ion channels, proteases, structural proteins, membrane transport proteins, nuclear hormone receptors, and mutations and combinations thereof. 10. The storage bag of claim 1 , wherein the therapeutic compound comprises at least one bioactive selected from selected from primary and embryonic stem cells. 11. The storage bag of claim 1 , wherein the storage bag is a cryopreservation bag. 12. The storage bag of claim 1 , comprising: a second composite sheet having a third side including the higher melting polymer and a fourth side formed of the lower melting polymer, wherein the second composite sheet is folded over the second joint with the fourth side including the lower melting polymer such that the lower melting polymer is engaged with the second joint to form a third lap seam over the second joint. 13. The storage bag of claim 1 , wherein the storage bag has a single reservoir. 14. A storage bag comprising: a body extending longitudinally from a first end of the bag to a second end of the bag, the body defining an inner surface and an outer surface, wherein the inner surface comprises a higher melting polymer and the outer surface comprises a lower melting polymer, wherein a portion of the inner surface overlaps a portion of the outer surface to form a first lap seam; a first joint at the first end; a second joint at the second end; and a composite sheet having a first side formed of a higher melting polymer and a second side formed of a lower melting polymer, wherein the composite sheet is folded over the first joint with the second side comprising the lower melting polymer engaging the first joint to form a second lap seam over the first joint, wherein, the first lap seam extends longitudinally from the first end to the second end, the first lap seam being positioned between opposing lateral edges of the bag to divide the bag into first and second sides, and wherein the storage bag contains therein at least one therapeutic compound. 15. The storage bag of claim 14 , wherein the therapeutic compound comprises viral vectors, non-viral vectors, and combinations thereof. 16. The storage bag of claim 15 , wherein the viral vectors include lentiviruses, adeno associated viruses (AAV), adenoviruses, alphaviruses, herpes simplex, measles virus, newcastle disease virus (NDV), picornaviruses, poxviruses, retroviruses, rhabdoviruses and combinations thereof. 17. The storage bag of claim 15 , wherein the viral vectors include lentiviruses and adeno associated viruses. 18. The storage bag of claim 17 , wherein the adeno associated viruses comprise AAV-MeCP2, AAV1, AAV5; Dual AAV9, AAV8, AAV9, AAVrh10, AAVhu37, AAV-FVIII/FIX, and mutations and combinations thereof. 19. The storage bag of claim 17 , wherein the lentiviruses comprise HIV-1, HIV-2, Lenti-FVIII, Lenti-FIX, and mutations and combinations thereof. 20. The storage bag of claim 14 , wherein the therapeutic compound comprises at least one bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides, signal transduction molecules, vaccines, and mutations and combinations thereof. 21. The storage bag of claim 14 , wherein the therapeutic compound comprises compound at least one bioactive selected from antibodies, antisense, RNA interference, target receptors, and mutations and combinations thereof. 22. The storage bag of claim 14 , wherein the therapeutic compound comprises a bioactive selected from coagulation factors, cytokines, epigenetic protein families, growth factors, hormones, peptides, signal transduction molecules, vaccines, and mutations and combinations thereof. 23. The storage bag of claim 14 , wherein the therapeutic compound comprises at least one bioactive selected from protein kinases, esterases, phosphatases, ion channels, proteases, structural proteins, membrane transport proteins, nuclear hormone receptors, and mutations and combinations thereof. 24. The storage bag of claim 14 , wherein the therapeutic compound comprises at least one bioactive selected from primary and embryonic stem cells. 25. The storage bag of claim 14 , wherein the storage bag is a cryopreservation bag.

Assignees

Inventors

Classifications

  • Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving · CPC title

  • A61J1/10Primary

    Bag-type containers · CPC title

  • Cooled holders, e.g. for medications, insulin, blood or plasma · CPC title

  • End- or aperture-closing arrangements or devices (valves of valve bags {B65D31/14}; closures of filled bags B65D77/10) · CPC title

  • Containers characterised by specific material properties · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11278471B2 cover?
A storage bag configured to contain or that contains at least one therapeutic compound such as a viral vector and non-viral vector is provided. In one embodiment, the storage bag contains a viral vector and/or a non-viral vector containing genetic material. The storage bag has two edges and two ends including a first face and a second face integrally joined at the two edges of the bag and defin…
Who is the assignee on this patent?
Gore & Ass
What technology area does this patent fall under?
Primary CPC classification A61J1/10. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).